摘要
小分子在细胞中选择性降解致病菌的研究对各种疾病包括癌症的治疗药物的发展是一种新的方法。我们和其他人已经开发了一系列的小分子化合物的混合蛋白敲除技术,称为SNIPERs(特异性和非遗传性的IAP依赖蛋白消除);和肽的嵌合分子,称为protacs(蛋白靶向嵌合分子),从而导致目标蛋白通过泛素-蛋白酶体途径选择性降解。这些化合物包括两种通过连接器链接的不同配体;一个是一种泛素连接酶配体,另一个是预计这些细胞中蛋白质交联的靶蛋白配体。从理论上讲,任何胞浆蛋白都可以通过这种技术完成降解的目标。到目前为止,几个针对具体诱导的致癌蛋白的泛素化和蛋白酶体降解各种致癌蛋白的SNIPERs和protacs已被开发,导致细胞死亡,生长停滞,或癌细胞迁移的影响。因此,这种蛋白敲除技术在癌症治疗方面有很大的潜力。
关键词: IAP,PROTAC(蛋白靶向嵌合分子),蛋白酶体,蛋白敲除,SNIPER(特异性和非遗传性的IAP依赖蛋白消除),泛素连接酶。
Current Cancer Drug Targets
Title:Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Volume: 16 Issue: 2
Author(s): Nobumichi Ohoka, Norihito Shibata, Takayuki Hattori and Mikihiko Naito
Affiliation:
关键词: IAP,PROTAC(蛋白靶向嵌合分子),蛋白酶体,蛋白敲除,SNIPER(特异性和非遗传性的IAP依赖蛋白消除),泛素连接酶。
摘要: Selective degradation of pathogenic proteins by small molecules in cells is a novel approach for development of therapeutic agents against various diseases, including cancer. We and others have developed a protein knockdown technology with a series of hybrid small compounds, called SNIPERs (Specific and Nongenetic IAP-dependent Protein ERasers); and peptidic chimeric molecules, called PROTACs (proteolysis-targeting chimeric molecules), which induce selective degradation of target proteins via the ubiquitin-proteasome pathway. These compounds include two different ligands connected by a linker; one is a ligand for a ubiquitin ligase and the other is a ligand for the target protein, which are expected to crosslink these proteins in cells. Theoretically, any cytosolic protein can be targeted for degradation by this technology. To date, several SNIPERs and PROTACs against various oncogenic proteins have been developed, which specifically induce polyubiquitylation and proteasomal degradation of the oncogenic proteins, resulting in cell death, growth arrest, or impaired migration of cancer cells. Thus, this protein knockdown technology has a great potential for cancer therapy.
Export Options
About this article
Cite this article as:
Nobumichi Ohoka, Norihito Shibata, Takayuki Hattori and Mikihiko Naito , Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy, Current Cancer Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1568009616666151112122502
DOI https://dx.doi.org/10.2174/1568009616666151112122502 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Transdermal Drug Delivery: A Step towards Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Hypoxic Tumor Microenvironment and Cancer Cell Differentiation
Current Molecular Medicine Therapeutic Potential of Functional MRI in the Squamous Cell Cancer of Head and Neck
Current Medical Imaging Melanoma: The Radiotherapeutic Point of View; Review of the Current Literature
Reviews on Recent Clinical Trials The Role of PEDF in Tumor Growth and Metastasis
Current Molecular Medicine Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews VEGF Signaling Regulates Cofilin and the Arp2/3-complex within the Axonal Growth Cone
Current Neurovascular Research Translational Research of Photodynamic Therapy with Acridine Orange which Targets Cancer Acidity
Current Pharmaceutical Design Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions
Current Genomics Nanoparticulate Drug Delivery Sytem for Cancer Therapy: Oppourtunities and Challenges
Recent Patents on Nanomedicine Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets The Use of PET for Radiotherapy
Current Medical Imaging The Human Trypanolytic Factor: A Drug Shaped Naturally
Infectious Disorders - Drug Targets Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention
Current Topics in Medicinal Chemistry Targeting Trail Towards the Clinic
Current Drug Targets Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Nanoplatforms for Promoting Osteogenesis in Ovariectomy-Induced Osteoporosis in the Experimental Model
Current Nanomedicine